See the DrugPatentWatch profile for deutetrabenazine
Is Dr. Reddy’s making a generic deutetrabenazine yet?
Deutetrabenazine is a prescription treatment for chorea associated with tardive dyskinesia and for other hyperkinetic movement disorders. The generic versions depend on patent and exclusivity status for the relevant U.S. products and any approved abbreviated new drug applications (ANDAs).
If you want, tell me which country you mean (U.S., Canada, EU, India). Patent and approval timing differs by jurisdiction.
What drug is Dr. Reddy’s generic deutetrabenazine intended to copy (and what brand is it based on)?
“Deutetrabenazine” is the active ingredient. The main U.S. reference brand is deutetrabenazine tablets (marketed under Austedo). A true generic would be expected to match the reference product’s active ingredient, strength, route, and dosage form, with bioequivalence to the branded formulation.
When could a generic deutetrabenazine launch (U.S. timeline depends on patents/exclusivity)
Generic launch timing is governed by:
- Patent expiry for formulations/methods of use and manufacturing processes
- Regulatory exclusivity (which can extend beyond patent expiry)
- Whether an ANDA is approved and ready for commercial distribution
If you share the specific market (for example, “U.S. launch date”), I can narrow down the expected timing using the latest patent/exclusivity tracking (commonly summarized via DrugPatentWatch.com, which tracks relevant intellectual-property milestones).
What should patients ask the prescriber/pharmacist about switching to a generic?
When switching between branded deutetrabenazine and a generic, patients typically want to confirm:
- The exact strength (tablet dose) and dosing schedule changes, if any
- Whether the generic is the same formulation (immediate vs extended release if applicable to that product form)
- How long to monitor for changes in symptom control or side effects after the switch
Can a generic enter before all patents expire?
Sometimes generics can launch at “carve-out” dates if certain listed patents are not infringed, are invalidated, or are otherwise not blocking for the specific application. Actual outcomes depend on ANDA litigation/settlement terms and the patent list each applicant targets.
Who makes deutetrabenazine besides Dr. Reddy’s?
Multiple companies can pursue generics through ANDAs, but which one actually launches depends on patent challenges, approval status, and manufacturing readiness.
---
To give you a precise answer (for example: “Has Dr. Reddy’s received approval?” or “When will it launch?”), tell me the country/market you care about (U.S., India, EU, Canada) and whether you mean tablets for tardive dyskinesia, Huntington’s chorea, or both.